- Home
- OGI vs LXRX Comparison
OGI vs LXRX Comparison
Compare OGI & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OGI
- LXRX
- Stock Information
- Founded
- OGI 2013
- LXRX 1995
- Country
- OGI Canada
- LXRX United States
- Employees
- OGI N/A
- LXRX N/A
- Industry
- OGI Biotechnology: Pharmaceutical Preparations
- LXRX Biotechnology: Pharmaceutical Preparations
- Sector
- OGI Health Care
- LXRX Health Care
- Exchange
- OGI Nasdaq
- LXRX Nasdaq
- Market Cap
- OGI 135.1M
- LXRX 124.4M
- IPO Year
- OGI N/A
- LXRX 2000
- Fundamental
- Price
- OGI $1.07
- LXRX $0.51
- Analyst Decision
- OGI
- LXRX Buy
- Analyst Count
- OGI 0
- LXRX 4
- Target Price
- OGI N/A
- LXRX $3.67
- AVG Volume (30 Days)
- OGI 484.7K
- LXRX 32.2M
- Earning Date
- OGI 05-13-2025
- LXRX 05-01-2025
- Dividend Yield
- OGI N/A
- LXRX N/A
- EPS Growth
- OGI N/A
- LXRX N/A
- EPS
- OGI N/A
- LXRX N/A
- Revenue
- OGI $115,451,336.00
- LXRX $31,081,000.00
- Revenue This Year
- OGI $50.11
- LXRX N/A
- Revenue Next Year
- OGI $16.16
- LXRX $63.36
- P/E Ratio
- OGI N/A
- LXRX N/A
- Revenue Growth
- OGI N/A
- LXRX 2481.48
- 52 Week Low
- OGI $0.85
- LXRX $0.28
- 52 Week High
- OGI $2.17
- LXRX $2.45
- Technical
- Relative Strength Index (RSI)
- OGI 52.89
- LXRX 53.30
- Support Level
- OGI $1.02
- LXRX $0.48
- Resistance Level
- OGI $1.11
- LXRX $0.60
- Average True Range (ATR)
- OGI 0.07
- LXRX 0.09
- MACD
- OGI 0.02
- LXRX 0.01
- Stochastic Oscillator
- OGI 84.62
- LXRX 42.86
About OGI Organigram Holdings Inc.
Organigram Global Inc is a licensed cultivator of cannabis and manufacturer of cannabis-derived goods in Canada. It is is focused on producing high-quality cannabis for adult recreational consumers. It has also developed and acquired a portfolio of legal adult-use recreational cannabis brands, including Edison, Holy Mountain, Big Bag O' Buds, SHRED, SHRED'ems, Monjour, Tremblant Cannabis, Trailblazer, BOXHOT and DEBUNK. Organigram operates facilities in Moncton, New Brunswick and Lac-Superieur, Quebec, with a dedicated edibles manufacturing facility in Winnipeg, Manitoba.
About LXRX Lexicon Pharmaceuticals Inc.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.